Specifying GMP Drug Substance Manufacturing for a Recombinant Glycosylated Serine Protease Biologic Supporting a Phase 1 Study: A Request-for-Proposal Framework

An early-phase clinical program for a biologic can be no better than the drug substance that supplies it. This article builds a request for proposal (RFP) for a contract manufacturing organization (CMO) to develop and execute a GMP drug substance campaign for a hypothetical recombinant, glycosylated serine protease intended for a first-in-human dose-escalation study in a severe acute inflammatory disease with a risk of multiple organ dysfunction. The class-level rationale is that an enzyme acting in the coagulation and inflammatory pathways has a narrow therapeutic window in which bleeding risk makes consistent potency, purity, and control of product variants the central manufacturing concerns. The RFP specifies a mammalian expression system, three GMP batches, release specifications with potency by two orthogonal activity assays, stability initiated at manufacture, an IND chemistry, manufacturing, and controls (CMC) section, a 15-month schedule, an indicative budget of USD 4.5 to 7.5 million, and weighted selection criteria. Recommendations address confidentiality and intellectual property.Keywords: request for proposal; recombinant glycoprotein; GMP drug substance; Phase 1; CMC; potency assay; ICH Q5A(R2); ICH Q6B

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24425459
Primary Topic
Protein purification and stability
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Specifying GMP Drug Substance Manufacturing for a Recombinant Glycosylated Serine Protease Biologic Supporting a Phase 1 Study: A Request-for-Proposal Framework

Peivand Pirouzi, Patricia Angelique Mallari
Zenodo (CERN European Organization for Nuclear Research)
Protein purification and stability
article

Specifying GMP Drug Substance Manufacturing for a Recombinant Glycosylated Serine Protease Biologic Supporting a Phase 1 Study: A Request-for-Proposal Framework

Peivand Pirouzi, Patricia Angelique Mallari
article en

Abstract

An early-phase clinical program for a biologic can be no better than the drug substance that supplies it. This article builds a request for proposal (RFP) for a contract manufacturing organization (CMO) to develop and execute a GMP drug substance campaign for a hypothetical recombinant, glycosylated serine protease intended for a first-in-human dose-escalation study in a severe acute inflammatory disease with a risk of multiple organ dysfunction. The class-level rationale is that an enzyme acting in the coagulation and inflammatory pathways has a narrow therapeutic window in which bleeding risk makes consistent potency, purity, and control of product variants the central manufacturing concerns. The RFP specifies a mammalian expression system, three GMP batches, release specifications with potency by two orthogonal activity assays, stability initiated at manufacture, an IND chemistry, manufacturing, and controls (CMC) section, a 15-month schedule, an indicative budget of USD 4.5 to 7.5 million, and weighted selection criteria. Recommendations address confidentiality and intellectual property.Keywords: request for proposal; recombinant glycoprotein; GMP drug substance; Phase 1; CMC; potency assay; ICH Q5A(R2); ICH Q6B

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Protein purification and stability
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Specifying GMP Drug Substance Manufacturing for a Recombinant Glycosylated Serine Protease Biologic Supporting a Phase 1 Study: A Request-for-Proposal Framework — Peivand Pirouzi, Patricia Angelique Mallari · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS